Materia and Peakdale Molecular Ltd. Collaborate to Commercialize Metathesis-Based Privileged Scaffolds
Published: Mar 01, 2007
PASADENA, Calif. & CHAPEL-EN-LE-FRITH, England--(BUSINESS WIRE)--Materia, Inc. and Peakdale Molecular Ltd. announced today their collaboration to offer metathesis-based scaffolds for the pharmaceutical industry. Under the agreement, Peakdale has acquired non-exclusive rights to practice Materia’s metathesis intellectual property portfolio for the design, development, and sale of research quantities of the scaffolds. The partners will jointly identify target compounds, while Peakdale will be primarily responsible for the compounds’ development, production, and initial distribution.